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Summary
Background Malignant pleural mesothelioma (MPM)
is a rare but aggressive tumor originating from the
pleural cavity with a strong link to previous asbestos
exposure. In order to determine the demographics,
diagnostics, therapeutic strategies, and prognosis of
MPM patients in Austria, the Austrian Mesothelioma
Interest Group (AMIG) was founded in 2011. In this re-
port the data from the AMIG MPM database collected
to date are reported.
Methods A prospective observational registry was ini-
tiated, including patients with histologically verified
All authors contribute on behalf of the Austrian
Mesothelioma Interest Group (AMIG).
T. Klikovits · Assist. Prof. Dr. M. A. Hoda () · Y. Dong ·
W. Klepetko
Division of Thoracic Surgery, Department of Surgery,
Comprehensive Cancer Center, Medical University Vienna,
Waehringer Guertel 18–20, 1090 Vienna, Austria
mir.hoda@meduniwien.ac.at
M. Arns
Department of Pulmonology, LKH Hochegg, Hochegg,
Austria
B. Baumgartner
Department of Pulmonology, Landeskrankenhaus
Vöklabruck, Vöklabruck, Austria
P. Errhalt
Department of Pulmonology, University Clinic Krems,
Krems, Austria
C. Geltner
Department of Pulmonology, Klinikum Klagenfurt,
Klagenfurt, Austria
B. Machan
Rehabilitation Center Tobelbad, Allgemeine
Unfallversicherungsanstalt, Tobelbad, Austria
MPM diagnosed and treated at specialized centers in
Austria. Patient inclusion started in January 2011 and
follow-up was completed until September 2015.
Results A total number of 210 patients were included.
There were 167 male and 43 female patients with
a mean age of 67.0 years (SD ± 11.3) at the time of
diagnosis. Asbestos exposure was confirmed in 109
(69.4%) patients. The histological subtype was ep-
ithelioid in 141 (67.2%), sarcomatoid in 16 (7.6%),
biphasic in 28 (13.3%), and MPM not otherwise
specified in 25 (11.9%) patients. Of the patients,
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30 (14.3%) received best supportive care (BSC) only,
71 (33.8%) chemotherapy (CHT) alone, four (1.9%)
radiotherapy (RT) alone, 23 (11.9%) CHT/RT, two
(0.9%) surgery alone, and 76 (36.2%) curative surgery
within a multimodality treatment (MMT), which was
more frequently performed for patients younger than
65 years and with early-stage disease (I + II). Me-
dian overall survival (OS) was 19.1 months (95% CI
14.7–23.5). The 1-, 3-, and 5-year OS rates were 66%,
30%, and 23%, respectively, and OS was significantly
better in patients undergoing surgery within MMT (5-
year survival 5% vs. 40%, p = 0.001).
Conclusion Patients with earlier disease stages,
younger age, good performance status, and epithe-
lioid histology were more likely to undergo MMT
including surgery, which resulted in a more favorable
outcome.
Keywords Malignant pleural mesothelioma · Tumor
registry · Epidemiology · Treatment · Outcome
Introduction
Mesothelioma is a rare malignant tumor arising from
mesothelial cells lining the pleural, pericardial, or
peritoneal cavity. The most common and most
aggressive type is malignant pleural mesothelioma
(MPM), which is strongly associated with previous
asbestos exposure. The incidence of MPM is between
1 and 2 in 100,000 and is still rising in most European
countries [1]. Clinical and pathological verification
is challenging and the majority of patients have ad-
vanced-stage disease at the time of the first diagnosis
[2]. The prognosis of the disease is dismal, with a me-
dian overall survival (OS) from 9 to 12 months [3].
Recently, the therapeutic management in early stages
has shifted from single-therapy approaches to multi-
modality treatment strategies including chemother-
apy (CHT), radiotherapy (RT), and radical surgery
[4, 5]. Nevertheless, local spread and extensive tu-
mor growth often prevent complete surgical removal.
Thus, the high mortality and early progression of
MPM is largely due to locoregional spread/recurrence
within the pleural space or transdiaphragmatically
into the abdominal cavity. Moreover, in advanced
stages, symptom control and palliative attempts are
needed for improved quality of life [6]. In order to
determine the demographics, diagnostics, therapeutic
strategies, and prognosis of patients with MPM, the
Austrian Mesothelioma Interest Group (AMIG) was
founded in 2011 involving all main centers treating
these patients in Austria. Detailed information about
the group can be obtained on the Internet (http://
www.amig.at). Several meetings were held and the
members of the AMIG decided to initiate a registry in
order to collect and evaluate data on epidemiology,
treatment, and outcome of MPM patients in Aus-
tria. These data were collected and analyzed from
the AMIG MPM database and are reported in this
manuscript.
Patients and methods
A prospective multi-institutional tumor registry was
initiated involving 25 different centers in Austria
(Fig. 1). Patients were included if MPM was histo-
logically verified between January 2011 and July 2015
regardless of stage and treatment modality. Cus-
tomized case report forms (CRF) were established
and contributing centers were required to transfer
CRFs to the AMIG coordination office at the Division
of Thoracic Surgery, Medical University of Vienna at
different time points: (1) at the time of diagnosis
of MPM, (2) at the beginning of treatment, (3) at
the end of treatment, and (4) at the last follow-up
or until death. Patients were diagnosed, staged,
and treated according to the common practice of
the individual institution. The latest International
Mesothelioma Interest Group (IMIG) staging system
was routinely applied [2]. Follow-up was completed
until September 2015. This prospective tumor registry
was approved by the ethics committee of the Medical
University of Vienna, serving as the leading ethics
committee for this multi-institutional study. All pro-
cedures followed were in accordance with the ethical
standards of the responsible committee on human
experimentation (institutional and national) and with
the Helsinki Declaration of 1975, as revised in 2008.
Individual patient consent was required and only pa-
tients who gave written consent were included. CRFs
were transferred to a digital database and data were
anonymously saved at the AMIG coordination office.
Interim analyses were presented at annual meetings
of the participating AMIG members.
Statistical analysis
Metric data are given as median and corresponding
range, or, in the case of survival, as median and cor-
responding 95% confidence interval (CI) if not other-
wise indicated. OS was defined as the time between
MPM diagnosis and death or, in censored patients,
diagnosis and last follow-up date. Survival was ana-
lyzed by the Kaplan–Meier method and log rank test
or by the Cox regression model to calculate hazard
ratios (HRs) and corresponding CIs. The χ2 test was
performed for analyzing the association between cat-
egorical factors. The correlation of metric data was
analyzed by Pearson’s correlation coefficient. The
threshold of significance was set at p < 0.05; p values
are given as two-sided. The SPSS V. 20 software pack-
age (IBM, Armonk, N.Y.) was used for all statistical
analyses.
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Fig. 1 Number of patients
includedby thedifferent
centers inAustria





























In total, 210 patients with histologically verified MPM
were included. There were 167 (79.5%) male and 43
(20.5%) female patients with a mean age of 67.0 years
(SD ± 11.3) at the time of diagnosis. Asbestos expo-
sure was confirmed in 109 (69.4%) patients. Smoking
history was known in 166 (79%) patients, of which
72 (43.4%) were never smokers, 73 (44%) former
smokers, and 21 (12.6%) current smokers. The mean
Karnofsky index at the time of diagnosis was 84.85
(SD ± 11.8). The histological subtype was epithelioid
in 141 (67.2%), sarcomatoid in 16 (7.6%), biphasic
in 28 (13.3%), and MPM not otherwise specified in
25 (11.9%) patients. Among the main initial symp-
toms, dyspnea of unclear origin (62.8%), recurrent or
persisting pleural effusion (41%), and thoracic pain
(29%) were most frequent (Table 1).
Diagnostic and staging procedures
Information on diagnostic and staging modalities was
available for 198 (94.3%) patients. In 164 (78.1%)
patients, a direct pleural biopsy was performed for
histological verification. Of these, 89 (53.3%) under-
went diagnostic video-assisted thoracoscopic biopsy.
In 18 (8.6%) patients, pleural puncture was successful
in establishing the diagnosis of MPM. In 198 (100%)
patients, computed tomography (CT) of the chest
was performed, 128 (64.6%) received additional com-
bined positron emission tomography (PET)/CT, and
21 (10.6%) a PET. Additional bronchoscopy was per-
formed on 25 (11.9%) patients. Data on initial staging
were available for 150 (71.4%) patients. Among these,
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Table 1 Basicdataof 210patientswithMPMdocumented
in theAMIGMPMregistry
Number (n) %
Gender (male), n = 210 167 79.5




Mean follow-up 468.4 days
Asbestos exposure, n = 157 109 69.4














































AMIG Austrian Mesothelioma Interest Group, MPM malignant pleural
mesothelioma, IMIG International Mesothelioma Interest Group, CT com-
puted tomography, PET positron emission tomography
Fig. 2 Overall survival of 185patientswithMPM
stages were distributed as follows: I, n = 26 (17.3%); II,
n = 23 (15.3%); III, n = 40 (26.7%); IV, n = 61 (40.7%)
(Table 1).
Treatment modalities and follow-up
In all, 30 (14.3%) patients received best support-
ive care (BSC) only, 71 (33.8%) chemotherapy (CHT)
alone, four (1.9%) radiotherapy (RT) alone, 23 (11.9%)
CHT/RT, two (0.9%) surgery alone, and 76 (36.2%)
curative surgery within a multimodality treatment
(MMT = surgery combined with either CHT, RT,
or CHT/RT). For four patients (1.9%), no data on
treatment were available. The most common type
of chemotherapy was a combination of cisplatin/
pemetrexed (n = 100), and various drugs and combi-
nations were used according to the treating oncolo-
gist. Surgical procedures consisted of 50 (23.8%) ex-
trapleural pneumonectomies (EPP), 19 (9%) pleurec-
tomy/decortications (P/D), and nine (4.3%) other
operations (e.g., partial pleurectomy en bloc with
adjacent lung tissue) with the intent of macroscopic
complete resection. In patients undergoing curative
intent surgery, the postoperative complication rate
was 21.8% (n = 17) and 30-day mortality was nil. Re-
evaluation and follow-up were routinely performed
in 3- to 6-month intervals with chest x-ray and chest
CT scan if necessary. At the end of the follow-up,
99 (47.1%) patients had died. Of these patients, the
cause of death was tumor related in 85 (85.9%) cases.
Survival
Sufficient data for survival analysis were available in
185 (88.1%) patients. Median OS was 19.1 months
(95% CI 14.7–23.5). The 1-, 3-, and 5-year OS was
66%, 30%, and 23%, respectively (Fig. 2). When Ka-
plan–Meier survival was calculated for performance
status measured by the Karnofsky index at the time
of diagnosis, survival curves showed appropriate dis-
crimination (Fig. 3). The survival analysis based on
the IMIG staging system revealed that MPM patients
with early-stage disease (I, II) had a significantly bet-
ter outcome than those with late-stage disease (III, IV;
median OS 26.4 vs. 13.0 months, HR 0.55, 95% CI
0.35–0.86, p = 0.002). Patients with epithelioid his-
tological subtype had improved OS compared with
those with non-epithelioid subtype (median OS 25.1
vs. 10.2 months, p = 0.003; Fig. 4). There was no sur-
vival difference between males and females and pa-
tients below or above the age of 65 years. Survival was
significantly improved in patients undergoing surgery
within multimodality treatment compared with pa-
tients with other treatment modalities (5-year survival
40% vs. 5%, p = 0.001; Fig. 5). However, patients
within MMT were significantly younger (age <65a, p =
0.001), had earlier-stage disease (stage I/II vs. III/IV,
p = 0.001), better performance status (mean Karnof-
sky index 87.6 vs. 83.2, p = 0.017), and more often had
epithelioid subtype (p = 0.001; Table 2). When per-
forming a multivariate Cox regression survival analy-
sis, performance status (HR 0.96, 95% CI 0.94–0.96,
p = 0.001) and histological subtype (non-epithelioid
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Fig. 3 Survival according
to theKarnofsky index re-
gardlessof histology, stage,
and treatment
vs. epithelioid, HR 1.8, 95% CI 1.06–3.07, p = 0.031)
remained the only significant cofactors (Table 3).
Discussion
The diagnosis, staging, and treatment of MPM pa-
tients still remain a challenging task for all involved
physicians. Guidelines and recommendations can
help to facilitate clinical practice. In order to estab-
lish a basis for developing such clinical guidelines,
meticulous and detailed MPM patient data collection
is mandatory. Therefore, we established the AMIG
database in 2011 aiming to improve MPM patient
care and management in Austria. Furthermore, the
analysis of the data should provide a general overview
of the current situation and patterns of care for MPM
patients all over the country. In the present report
on the prospective MPM database of the AMIG, we
were able to analyze a large cohort of 210 consecutive
patients treated in several Austrian hospitals.
Although the usage of asbestos is forbidden in
many countries worldwide, previous exposure to as-
bestos remains the main risk factor for the develop-
ment of MPM. In our cohort, asbestos exposure was
confirmed in 69% of the included patients. In almost
all cases, patients had occupation-related asbestos ex-
posure and these were predominantly male patients.
This is well in line with the published literature with
a series from France, a recent paper on a large cohort
from Belgium, The Netherlands, and England, and
a series from Australia on MPM epidemiology [7–9].
This is particularly important since the development
of MPM has a latency period of up to 30 years from
the time of exposure and the peak of MPM incidence
is expected to be between 2020 and 2025 in Europe.
For this reason, early diagnosis and treatment will
become even more important in the future, especially
in patients with previous occupational exposure. To
date, there are no validated biomarkers for early MPM
detection available and hence appropriate early di-
agnostic and staging procedures are mandatory in
patients suspected of having MPM. With regard to
diagnosis, 78% of patients in the present series were
diagnosed via pleural biopsy. Video-assisted thoraco-
scopic pleural biopsy was the procedure of choice for
obtaining histological verification in the majority of
cases as recommended by the latest published guide-
lines [4, 10, 11]. The epithelioid subtype was the most
common histology, as in all larger published series
and in the database of the International Association
for the Study of Lung Cancer (IASLC) [8, 12–14].
Appropriate staging of MPM can be challenging
and is important for therapeutic decision making.
Staging by PET/CTwas undertaken in 64% of patients,
representing the most common staging procedure for
this disease in Austria. According to the literature, it
is mainly recommended as part of a study protocol
in order to locate tumor sites, distant metastasis, and
possible nodal involvement, and is useful for assessing
early response to treatment. As advocated by many
different clinical guidelines, the most recent TNM-
based IMIG classification was commonly used in this
cohort [15]. Further staging methods such as magnet
resonance imaging (MRI), exploratory laparoscopy,
or mediastinoscopy/endobronchial ultrasound fine
needle aspiration (EBUS-TBNA) have not been ap-
plied uniformly. As there is no clear evidence of these
methods in the staging of MPM, this remains an area
for further investigation.
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Fig. 4 Survival inpatientswithmalignantpleuralmesothe-
liomaaccording to histology (a) and stage (b)
The majority of the patients in the AMIG cohort
were diagnosed with MPM of stages III and IV, and
therefore chemotherapy was the most common treat-
ment option in this series. In all, 100 patients re-
ceived the combination of platinum and pemetrexed,
which has been the standard chemotherapy proto-
col used since 2003 worldwide [16]. However, other
chemotherapy protocols were also used, according to
the physician’s choice. Symptom control by best sup-
portive care was achieved in 30 patients. This is par-
ticularly important since older patients with reduced
performance status are not able to undergo therapy
with curative intention and hence improvement of
quality of life becomes even more important.
Fig. 5 Survival of patientsundergoing surgerywithinmulti-
modality treatment (MMT) comparedwithpatientswithother
treatmentmodalities
The impact of surgery on patient survival in MPM
has been well described in the past and is a partic-
ularly important component in multimodality treat-
ment protocols [12, 13, 17]. Macroscopic complete
resection (MCR) has been defined as the ultimate
goal for surgery with curative intent [18]. In the
AMIG cohort, 76 patients received MCR as part of
a multimodality protocol. With regard to surgical pro-
cedures, extrapleural pneumonectomy (EPP) was the
most common surgical technique followedby pleurec-
tomy/decortication (P/D). Both techniques have been
standardized in the framework of a consensus report
on surgical techniques [15]. Postoperative complica-
tions were present in 21.8% of patients and 30-day
mortality was nil in this analysis. These data are com-
pare well with large published series on the outcome
of different surgical techniques [13, 19–22].
Despite tremendous efforts in all fields of therapy,
especially surgery and systematic treatment, the sur-
vival of MPM patients still remains poor. Only well-
selected patients can achieve more than 3 years of sur-
vival. In our unselected patient cohort, the median
OS was 19.1 months with a 3- and 5-year survival of
30% and 23%, respectively. These survival rates are
in line with or superior to the survival data of larger
prospective and retrospective studies in MPM treat-
ment [5, 8, 9]. Analysis of prognostic factors for sur-
vival in the AMIG database revealed that the Karnof-
sky index at the time of diagnosis, early stages accord-
ing to the IMIG staging system, epithelioid histology,
and surgery within multimodality treatment had a fa-
vorable impact on outcome. Similar co-factors have
been determined by the IASLC database and are part
of two widely used prognostic scores [14, 23]. Inter-
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Table 2 Comparisonof clinical parametersbetweenpa-
tientsundergoing surgerywithinmultimodality treatment






n % n %
Gender (male) 57 75 110 82.1 NS

















































NS not significant, IMIG International Mesothelioma Interest Group, MMT
multimodality treatment
Table 3 MultivariateCox regressionanalysis for survival
adjusted for clinical factors
HR p 95% CI
Lower Upper
Gender Female 1 – – –
Male 0.57 0.074 0.31 1.06
Age >65 1 – – –
<65 1.61 0.10 0.91 2.86
Karnofsky index (continu-
ous)
0.96 0.001 0.94 0.96
Histology Epithelioid 1 – – –
Non-epi-
thelioid
1.80 0.031 1.06 3.07
Stage Early 1 – – –
Late 1.36 0.27 0.79 2.35
Treatment MMT 1 – – –
Other 1.72 0.075 0.95 3.12
MMT multimodality treatment, HR hazard ratio, CI confidence interval
estingly, there was no difference in survival in patients
according to age. Moreover, we did not observe any
significant survival difference with regard to gender.
However, in a recent publication, a threefold better
survival rate in female than in male patients was re-
ported, irrespectively of age, stage, and treatment [24].
In summary, we report on the first nationwide
mesothelioma database in Austria. Our initial analy-
sis reveals comparable practice in the management of
MPM patients in different participating institutions.
The diagnosis, staging, treatment, and outcome of
this patient cohort are well in line with international
guidelines and experiences of larger centers world-
wide. However, these data serve as a starting point for
future collaborative efforts within Austria. Prospec-
tive clinical studies, especially on new treatment
strategies, are warranted to optimize outcome in this
devastating disease.
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